Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EORTC 2120-HNCG: Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck squamous cell carcinoma (Ravina)
2022-502339-20-00Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised trial in head and neck squamous cell carcinoma (HNSCC) comparing Radiotherapy + xevinapant with Radiotherapy + placebo (2 arms). Primary endpoint: Locoregional event-free survival. Started Jul 2023; status: completed.
02
Drugs
xevinapant
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2022-502339-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502339-20-00.